Recent genomic breakthroughs have revolutionized our understanding of cancer. It is now possible to envision treatment paradigms that would be individualized, targeted and tailored according to the tumor genetic profile. However, high-throughput functional assays capable of identifying and validating potential cancer drugs, based on abnormal tumor gene expression profiles, in a setting that would directly translate to providing recommendations for patient treatment are not readily available. The human tumor stem cell assay (HTSCA), also known as anchorage-independent growth assay, has been considered as the ""gold standard"" for chemosensitivity testing of patient tumor cells. In its current format, the HTSCA suffers from many pitfalls that make it unfit for high-throughput clinical testing. Falcon Genomics, Inc. is developing the Cancer BioChip System (CBCS), a rapid, high-throughput, automated, and quantitative anchorage-independent growth assay for the personalized identification and validation of inhibitors of cancer cell growth. We will use silencing RNA (siRNA) or short hairpin RNA (shRNA) to inhibit expression of abnormally expressed tumor genes and test their impact on anchorage-independent tumor growth in a high-throughput fashion. In this Phase I application, we will develop a Test Cancer BioChip for optimizing plating, transfection, silencing, and cytostatic efficiencies. Results from these studies will validate the CBCS as a tool for cancer target identification and validation. Through future clinical trials, we anticipate development of the CBCS into a cancer diagnostic and personalized therapeutic tool. , ,
Public Health Relevance: This Phase-1 grant application is relevant to the mission of the National Institute of Health since it will provide for a Cancer BioChip System that will assist in the diagnosis and development of cancer therapies. It will initially offer a novel personalized approach to the evaluation and treatment of breast cancer patients. However, it is not limited to breast cancer since all types of cancers that are capable of growing in an anchorage-independent fashion can be tested on the Cancer BioChip System.
Thesaurus Terms: Agar;Agents, Cytostatic;Anchorage-Independent Growth;Anti-Cancer Agents;Anti-Tumor Agents;Anti-Tumor Drugs;Antineoplastic Agents;Antineoplastic Drugs;Antineoplastics;Antiproliferative Agents;Antiproliferative Drugs;Applications Grants;Assay;Au Element;Bioassay;Biologic Assays;Biological Assay;Breast Cancer Cell;Cancer Cause;Cancer Cell Growth;Cancer Diagnostics;Cancer Drug;Cancer Etiology;Cancer Genes;Cancer Patient;Cancer Treatment;Cancer Of Breast;Cancer-Promoting Gene;Cancers;Cells;Cellular Transformation;Chemosensitivity Assay;Chemosensitivity Testing;Chemotherapeutic Agents, Neoplastic Disease;Clinical Evaluation;Clinical Testing;Clinical Trials;Clinical Trials, Phase Iii;Clinical Trials, Unspecified;Clonogenic Cell Assay, Tumor;Colony-Forming Units Assay, Tumor;Computer Programs;Computer Software;Custom;Cytostatic Drugs;Cytostatics;Dna Chips;Dna Microarray;Dna Microarray Chip;Dna Microchips;Development;Devices;Diagnosis;Diagnostic Tests;Disease Progression;Drugs;Effectiveness;Equipment;Evaluation;Expression Profiling;Expression Signature;Future;Gene Expression;Gene Products, Rna;Gene Targeting;Generalized Growth;Generations;Genes;Genomics;Gold;Grant Proposals;Grants, Applications;Growth;High Throughput Assay;Human;Human Breast Cancer Cell;Human, General;Image;Image Analyses;Image Analysis;Label;Life;Malignant Cell;Malignant Neoplasm Therapy;Malignant Neoplasm Treatment;Malignant Neoplasms;Malignant Tumor;Malignant Tumor Of The Breast;Malignant Neoplasm Of Breast;Man (Taxonomy);Man, Modern;Marketing;Mediating;Medication;Microarray Analysis;Microarray-Based Analysis;Microscopic;Mission;Molecular Fingerprinting;Molecular Profiling;Monitor;Nih;National Institutes Of Health;National Institutes Of Health (U.S.);Neoplasm Stem Cell Assay;Oncogenes;One Step;One-Step Dentin Bonding System;Outcome;Patient Selection;Patients;Performance;Pharmaceutic Preparations;Pharmaceutical Preparations;Phase;Phase 3 Clinical Trials;Phase Iii Clinical Trials;Post-Transcriptional Gene Silencing;Post-Transcriptional Gene Silencings;Posttranscriptional Gene Silencing;Posttranscriptional Gene Silencings;Quelling;Rna;Rna Interference;Rna Silencing;Rna Silencings;Rna, Non-Polyadenylated;Rnai;Roc Analysis;Reagent;Recommendation;Recurrence;Recurrent;Ribonucleic Acid;Robot;Role;Sampling;Screening Procedure;Sequence-Specific Posttranscriptional Gene Silencing;Services;Software;Solutions;System;System, Loinc Axis 4;Targetings, Gene;Testing;Therapeutic;Tissue Growth;Transfection;Transforming Genes;Translating;Translatings;Tumor Cell;Tumor Stem Cell Assay;Tumor-Specific Treatment Agents;United States National Institutes Of Health;Validation;Variant;Variation;Anticancer Agent;Anticancer Drug;Anticancer Therapy;Base;Biochip;Cancer Cell;Cancer Therapy;Cancer Type;Cell Imaging;Cellular Imaging;Clinical Investigation;Clinical Test;Computer Program/Software;Cost;Density;Design;Designing;Drug/Agent;Genetic Profiling;High Throughput Screening;Image Evaluation;Imaging;In Vivo;Inhibitor;Inhibitor/Antagonist;Language Translation;Malignancy;Malignant Breast Neoplasm;Meetings;Metaplastic Cell Transformation;Microarray Technology;Miniaturize;Molecuar Profile;Molecular Signature;Neoplasm/Cancer;Neoplastic Cell;Novel;Ontogeny;Phase 3 Study;Phase 3 Trial;Phase Iii Trial;Protocol, Phase Iii;Public Health Relevance;Research Clinical Testing;Screening;Screenings;Shrna;Short Hairpin Rna;Small Hairpin Rna;Social Role;Study, Phase Iii;Technological Innovation;Therapeutic Target;Tool;Tumor;Tumor Growth
